187 related articles for article (PubMed ID: 33563316)
1. Risk of hematological malignancies in the families of patients treated for nodular lymphocyte-predominant Hodgkin lymphoma.
Akhtar S; Rauf MS; Al-Kofide A; Elshenawy MA; Mushtaq AH; Maghfoor I
Hered Cancer Clin Pract; 2021 Feb; 19(1):17. PubMed ID: 33563316
[TBL] [Abstract][Full Text] [Related]
2. High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma.
Saarinen S; Pukkala E; Vahteristo P; Mäkinen MJ; Franssila K; Aaltonen LA
J Clin Oncol; 2013 Mar; 31(7):938-43. PubMed ID: 23284040
[TBL] [Abstract][Full Text] [Related]
3. [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Li L; Luo XL
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):594-8. PubMed ID: 17243292
[TBL] [Abstract][Full Text] [Related]
4. Flow Cytometric Detection of the Double-Positive (CD4+CD8+)/PD-1bright T-Cell Subset Is Useful in Diagnosing Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Chen ZW; Wizniak J; Shang C; Lai R
Arch Pathol Lab Med; 2022 Jun; 146(6):718-726. PubMed ID: 34506624
[TBL] [Abstract][Full Text] [Related]
5. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells.
Seliem RM; Ferry JA; Hasserjian RP; Harris NL; Zukerberg LR
J Hematop; 2011 Sep; 4(3):175. PubMed ID: 32288859
[TBL] [Abstract][Full Text] [Related]
6. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Moore EM; Swerdlow SH; Gibson SE
Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
[TBL] [Abstract][Full Text] [Related]
7. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma.
Boudová L; Torlakovic E; Delabie J; Reimer P; Pfistner B; Wiedenmann S; Diehl V; Müller-Hermelink HK; Rüdiger T
Blood; 2003 Nov; 102(10):3753-8. PubMed ID: 12881319
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
Eichenauer DA; Fuchs M
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444420
[TBL] [Abstract][Full Text] [Related]
9. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma.
Nam-Cha SH; Roncador G; Sanchez-Verde L; Montes-Moreno S; Acevedo A; Domínguez-Franjo P; Piris MA
Am J Surg Pathol; 2008 Aug; 32(8):1252-7. PubMed ID: 18594468
[TBL] [Abstract][Full Text] [Related]
10. Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?
Barber NA; Loberiza FR; Perry AM; Bast M; Holdeman KP; Esfahane AB; Weisenburger DD; Vose J; Bierman P; Armitage JO; Bociek RG
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):392-7. PubMed ID: 23773450
[TBL] [Abstract][Full Text] [Related]
11. Atypical variants of nodular lymphocyte-predominant Hodgkin lymphoma show low microvessel density and vessels of distention type.
Scheidt V; Hansmann ML; Schuhmacher B; Döring C; Hartmann S
Hum Pathol; 2017 Feb; 60():129-136. PubMed ID: 27816718
[TBL] [Abstract][Full Text] [Related]
12. SUMO1 modification of histone H4 is involved in the pathogenesis of nodular lymphocyte predominant Hodgkin lymphoma.
Li H; Guo L; Li B; Li X
Transl Cancer Res; 2020 Jul; 9(7):4413-4423. PubMed ID: 35117806
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; Sasse S; Baues C; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
J Clin Oncol; 2020 Mar; 38(7):698-705. PubMed ID: 31626571
[TBL] [Abstract][Full Text] [Related]
14. Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics.
Younes S; Rojansky RB; Menke JR; Gratzinger D; Natkunam Y
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208705
[TBL] [Abstract][Full Text] [Related]
15. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma.
Hartmann S; Döring C; Vucic E; Chan FC; Ennishi D; Tousseyn T; de Wolf-Peeters C; Perner S; Wlodarska I; Steidl C; Gascoyne RD; Hansmann ML
Br J Haematol; 2015 May; 169(3):415-22. PubMed ID: 25644177
[TBL] [Abstract][Full Text] [Related]
16. An overview of genetic predisposition to familial hematological malignancies.
Hamadou WS; Bouali N; Besbes S; Mani R; Bardakci F; Siddiqui AJ; Badraoui R; Adnan M; Sobol H; Soua Z
Bull Cancer; 2021; 108(7-8):718-724. PubMed ID: 34052033
[TBL] [Abstract][Full Text] [Related]
17. Utility of fascin and JunB in distinguishing nodular lymphocyte predominant from classical lymphocyte-rich Hodgkin lymphoma.
Bhargava P; Pantanowitz L; Pinkus GS; Pinkus JL; Paessler ME; Roullet M; Gautam S; Bagg A; Kadin ME
Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):16-23. PubMed ID: 19550297
[TBL] [Abstract][Full Text] [Related]
18. Microenvironmental immune cell alterations across the spectrum of nodular lymphocyte predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma.
Panayi C; Akarca AU; Ramsay AD; Shankar AG; Falini B; Piris MA; Linch D; Marafioti T
Front Oncol; 2023; 13():1267604. PubMed ID: 37854674
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
20. Role of FNA with core biopsy or cell block in patients with nodular lymphocyte-predominant Hodgkin lymphoma.
Gupta S; Long SR; Natkunam Y; Kong CS; Gupta NK; Gratzinger D
Cancer Cytopathol; 2020 Aug; 128(8):570-579. PubMed ID: 32343479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
